Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27761091 | 0.96 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTKMT2AMEN1 | |
| SCHEMBL4354051 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAHTTKMT2AMEN1 | |
| SCHEMBL4346126 | 0.83 | LMNA (0.61) | SMN1; SMN2LMNAHTTKMT2AMEN1 | |
| SCHEMBL4343691 | 0.83 | EPHX1 (0.60) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL17956795 | 0.80 | HTT (0.70) | SMN1; SMN2LMNAHTTKMT2AMEN1 | |
| SCHEMBL17956794 | 0.80 | HTT (0.70) | SMN1; SMN2LMNAHTTKMT2AMEN1 | |
| SCHEMBL27782801 | 0.79 | LMNA (0.67) | SMN1; SMN2LMNAHTTKMT2AMEN1 | |
| SCHEMBL27782774 | 0.79 | RECQL (0.62) | SMN1; SMN2LMNAHTTKMT2AMEN1 | |
| SCHEMBL4356323 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAHTTKMT2AMEN1 | |
| SCHEMBL8443237 | 0.78 | LMNA (0.65) | SMN1; SMN2LMNAHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | SMN1; SMN2 1791/4885LMNA 3160/4885HTT 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.